These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39117290)

  • 21. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
    Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
    Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insight into Cisplatin-Resistance Signaling of W1 Ovarian Cancer Cells Emerges mTOR and HSP27 as Targets for Sensitization Strategies.
    Wantoch von Rekowski K; König P; Henze S; Schlesinger M; Zawierucha P; Januchowski R; Bendas G
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287446
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-inhibition of Pol η and ATR sensitizes cisplatin-resistant non-small cell lung cancer cells to cisplatin by impeding DNA damage repair.
    Li XQ; Ren J; Chen P; Chen YJ; Wu M; Wu Y; Chen K; Li J
    Acta Pharmacol Sin; 2018 Aug; 39(8):1359-1372. PubMed ID: 29849128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chloroquine reverses chemoresistance via upregulation of p21
    Hwang JR; Kim WY; Cho YJ; Ryu JY; Choi JJ; Jeong SY; Kim MS; Kim JH; Paik ES; Lee YY; Han HD; Lee JW
    Cell Death Dis; 2020 Dec; 11(12):1034. PubMed ID: 33277461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance.
    Zheng H; Shao F; Martin S; Xu X; Deng CX
    Sci Rep; 2017 Mar; 7():43517. PubMed ID: 28262781
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Withaferin A inhibits expression of ataxia telangiectasia and Rad3-related kinase and enhances sensitivity of human breast cancer cells to cisplatin.
    Hahm ER; Lee J; Abella T; Singh SV
    Mol Carcinog; 2019 Nov; 58(11):2139-2148. PubMed ID: 31441116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identifying novel hypoxia-associated markers of chemoresistance in ovarian cancer.
    McEvoy LM; O'Toole SA; Spillane CD; Martin CM; Gallagher MF; Stordal B; Blackshields G; Sheils O; O'Leary JJ
    BMC Cancer; 2015 Jul; 15():547. PubMed ID: 26205780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
    Haynes B; Murai J; Lee JM
    Cancer Treat Rev; 2018 Dec; 71():1-7. PubMed ID: 30269007
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
    Hur J; Ghosh M; Kim TH; Park N; Pandey K; Cho YB; Hong SD; Katuwal NB; Kang M; An HJ; Moon YW
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33513721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer.
    Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W
    J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Knockdown of REV3 synergizes with ATR inhibition to promote apoptosis induced by cisplatin in lung cancer cells.
    Jiang HG; Chen P; Su JY; Wu M; Qian H; Wang Y; Li J
    J Cell Physiol; 2017 Dec; 232(12):3433-3443. PubMed ID: 28075014
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian and uterine carcinosarcomas are sensitive in vitro and in vivo to elimusertib, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor.
    Manavella DD; McNamara B; Harold J; Bellone S; Hartwich TMP; Yang-Hartwich Y; Mutlu L; Zipponi M; Demirkiran C; Verzosa MS; Altwerger G; Ratner E; Huang GS; Clark M; Andikyan V; Azodi M; Schwartz PE; Dottino PR; Choi J; Alexandrov LB; Buza N; Hui P; Santin AD
    Gynecol Oncol; 2023 Feb; 169():98-105. PubMed ID: 36525930
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Suppression of ATR reverses the cisplatin resistance in ovarian cancer SKOV3 cells].
    Yang Z; Sun C; Liu Y; Gong C; Chen G; Weng D
    Zhonghua Zhong Liu Za Zhi; 2014 Nov; 36(11):805-10. PubMed ID: 25620475
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Ali AY; Abedini MR; Tsang BK
    Oncogene; 2012 Apr; 31(17):2175-86. PubMed ID: 21927021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theasaponin E
    Li B; Tong T; Ren N; Rankin GO; Rojanasakul Y; Tu Y; Chen YC
    Molecules; 2021 Mar; 26(6):. PubMed ID: 33802884
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cdc6 contributes to cisplatin-resistance by activation of ATR-Chk1 pathway in bladder cancer cells.
    Chen S; Chen X; Xie G; He Y; Yan D; Zheng D; Li S; Fu X; Li Y; Pang X; Hu Z; Li H; Tan W; Li J
    Oncotarget; 2016 Jun; 7(26):40362-40376. PubMed ID: 27246979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.
    Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H
    Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Promotion of Cell Death in Cisplatin-Resistant Ovarian Cancer Cells through KDM1B-DCLRE1B Modulation.
    Lee YK; Lim J; Yoon SY; Joo JC; Park SJ; Park YJ
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108893
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
    Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
    Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Smith HL; Willmore E; Prendergast L; Curtin NJ
    Br J Cancer; 2024 Sep; 131(5):905-917. PubMed ID: 38965423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.